share_log
Reuters ·  Mar 10 12:00
Northstrive Biosciences Inc. Schedules Pre-Ind Meeting With FDA for El-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination With GLP-1
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Write a comment